Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 4776 - 4800 of 6524 in total
Investigational
Investigational
Ergidina is a recombinant human minibody against complement component C5 fused with RGD-motif.
Investigational
Ifidancitinib is under investigation in clinical trial NCT03585296 (A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis).
Investigational
Matched Iupac: … 5-({2-[(4-fluoro-3-methoxy-5-methylphenyl)amino]-5-methylpyrimidin-4-yl}amino)-2,3-dihydro-1,3-benzoxazol …
Diazepinomicin has been used in trials studying the treatment of Glioblastoma Multiforme. It is a proprietary first-in-class small molecule with the potential to treat multiple solid tumours like the well known chemotherapeutics, doxorubicin and mitomycin C. Diazepinomicin is a natural product derived from a non-pathogenic micro-organism. Discovered using Thallion’s DECIPHER...
Investigational
Experimental
Matched Iupac: … 5-ethenyl-5-(pentan-2-yl)-1,3-diazinane-2,4,6-trione …
Investigational
Experimental
Matched Iupac: … [(1E,5S)-5-amino-5-carboxypent-1-en-1-yl]trihydroxyboranuide …
Pf03635659 has been used in trials studying the treatment of Chronic Obstructive Pulmonary Disease.
Investigational
Matched Iupac: … 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide …
CAN-106 a novel, long-acting monoclonal antibody directed against human complement C5.
Investigational
Displaying drugs 4776 - 4800 of 6524 in total